These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10680422)

  • 1. The drug war.
    Meyer CR
    Minn Med; 2000 Jan; 83(1):2, 57. PubMed ID: 10680422
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 3. Downward pressure on US drug prices if Kerry wins.
    Andrawiss M
    Drug Discov Today; 2004 Oct; 9(20):861. PubMed ID: 15475314
    [No Abstract]   [Full Text] [Related]  

  • 4. US drug industry bans expensive freebies for MDs, Canada raises fines.
    Sibbald B
    CMAJ; 2002 Sep; 167(5):522. PubMed ID: 12240824
    [No Abstract]   [Full Text] [Related]  

  • 5. Obstacles and opportunities in new drug development.
    Kaitin KI
    Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
    [No Abstract]   [Full Text] [Related]  

  • 6. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 7. The new drug war.
    Parloff R
    Fortune; 2004 Mar; 149(5):144-6, 148, 150 passim. PubMed ID: 15015428
    [No Abstract]   [Full Text] [Related]  

  • 8. Rx: Canadian drugs.
    Bugden S
    N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15014193
    [No Abstract]   [Full Text] [Related]  

  • 9. World's first nonprofit drug company launched.
    Cassels A
    CMAJ; 2003 Sep; 169(6):590. PubMed ID: 12975232
    [No Abstract]   [Full Text] [Related]  

  • 10. [Development of new drugs is too expensive].
    Andreasen J
    Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug assistance from drug makers.
    Hanson K
    State Legis; 2003 Jun; 29(6):22-4. PubMed ID: 12785350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical manufacturers seek OIG comfort.
    Becker S
    Health Care Law Mon; 2002 Aug; ():3-6. PubMed ID: 12420396
    [No Abstract]   [Full Text] [Related]  

  • 13. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 14. The high cost of free drug samples.
    Kleiner JA
    Urol Nurs; 2012; 32(1):8-9, 51. PubMed ID: 22474860
    [No Abstract]   [Full Text] [Related]  

  • 15. Extraordinary claims require extraordinary evidence.
    Light DW; Warburton RN
    J Health Econ; 2005 Sep; 24(5):1030-3; discussion 1034-53. PubMed ID: 16087260
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescription drug expenditures rising--too fast?
    CMAJ; 2005 May; 172(10):1261, 1263. PubMed ID: 15883389
    [No Abstract]   [Full Text] [Related]  

  • 17. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 18. [Does the public sector have an independent research role in the development of drugs?].
    Poulsen HE; Grønlykke TB
    Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To sell their drugs, companies increasingly rely on doctors.
    Hensley S; Martinez B
    Wall St J (East Ed); 2005 Jul; ():A1,A2. PubMed ID: 16134281
    [No Abstract]   [Full Text] [Related]  

  • 20. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.